Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Sine Baisheng Pharmaceutical is a core subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH), one of China's largest pharmaceutical conglomerates. Operating under the prestigious "Sine" (Xinyi) brand, which has a history dating back to 1916, the company focuses on the manufacturing, marketing, and distribution of a diverse portfolio of chemical drugs and preparations. Its product range spans several critical therapeutic areas, including cardiovascular health, gastroenterology, and anti-infectives, with well-known products such as Trimetazidine and various gastrointestinal agents. Sine Baisheng serves as a critical commercial platform within the SPH ecosystem, integrating R&D insights with large-scale production and an extensive distribution network. The company is committed to maintaining high GMP standards and expanding its footprint in both domestic and international markets. It plays a vital role in the "Sine" division's strategy to provide affordable and high-quality essential medicines to the Chinese healthcare system.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Xinyi Baisheng Pharmaceutical.